Navigation Links
FDA Agrees With AtheroNova's Clinical Development Plan as Proposed
Date:12/14/2011

revention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain natural compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are then removed by natural body processes. AtheroNova plans to develop multiple applications for its patents-pending compounds that can be used in pharmaceutical-grade products for the treatment of atherosclerosis. Atherosclerosis and related pharmaceutical costs run more than $41 billion annually in the United States alone. Market sectors potentially served by AHRO-001 include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis.

About AtheroNova

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis, obesity and lipomas.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding FDA guidance, filing of an IND application, clinical measurement of plaque using intravascular/near-infrared spectroscopy and Phase I and II clinical studies, and the development of applications for AtheroNova's technology
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Zimmer Holdings, Inc. Agrees to Sell $550 Million of Senior Notes
2. 1-800-GET-THIN Agrees With Report Calling for Better Eating Habits
3. ARAMARK Agrees to Sell its Galls Business to CI Capital Partners
4. Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
5. Valeant Pharmaceuticals Agrees to Acquire Dermik
6. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
7. Devicor™ Medical Products, Inc. Agrees to Acquire Neoprobes Gamma Detection Devices
8. Biofield Corporations 51% Owned Subsidiary Agrees to Deal Appointing McKinley Infocapital as Korean Exclusive Distributor of Breast Cancer Diagnostic System; Contract has Potential Value of up to $15.3 Million
9. Quest Diagnostics Agrees to Repurchase 15.4 Million Shares From Largest Shareholder
10. Xanodyne Agrees to Withdraw Propoxyphene From the U.S. Market
11. Boston Scientific Agrees to Sell Neurovascular Business to Stryker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ), ... sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine ... announced the business and development progress at its Jiangchuan ... the September 2014 JCM application (No. 51268) for the ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... focus on Omega-3 therapies for cardiovascular disease and overall health ... Company,s accomplishments in 2014 and its outlook for 2015 from ... Fellow Shareholders, We would like to take this ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) ... Diagnostics Market by Product, Application, Technology, End User - ... , The infectious disease diagnostics market is ... $18,156.2 million by 2019 from $12,422.8 million in 2014. ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... Baxter,International Inc. today announced final Phase I/II data ... to initiate a Phase III clinical trial of ... results. , The Phase I/II study indicated that ... doses, and induces substantial,levels of cross immunity against ...
... Dr. H. Bryan Brewer, Jr. Sees Enormous Potential ... (MARKET WIRE via COMTEX News Network),-- Lipid Sciences, ... Scientific Director of Lipid Sciences, Inc., concluded from,the ... College of,Cardiology (ACC) Meeting in New Orleans that ...
Cached Medicine Technology:Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 2Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 3Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 4Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 5Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 2Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 4Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 5
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... 22, 2015 State Forestry Institute of ... system with support from GEOSYSTEMS, a dedicated Hexagon Geospatial ... will leverage Hexagon Geospatial’s ERDAS APOLLO for ... well as point clouds and documents. This effort will ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... LA CROSSE, Wis., April 21 When Gundersen Lutheran Health ... for the 1 to 2 percent decrease that,s common at ... more reduction in less than two years. That,s 9,600 metric ... the environment, the equivalent of removing 1,631 cars from the ...
... NeoGenomics, Inc. (NASD OTC BB: NGNM) ... quarter 2009 financial results on Thursday, April 23, 2009.The Company ... Q1 2009 results on April 23, 2009, at 11:00 AM ... (201) 689-8049 (international) at least five minutes prior to the ...
... Exposition Park LOS ANGELES, ... Dimes premier fundraising event that benefits all babies--those born healthy ... walkers are expected at this largest March for Babies event ... at the corner of S. Figueroa and 39th St., Los ...
... Features Gold Glove Outfielder Nate McLouth, Three Teen ... in partnership with the Pittsburgh Pirates baseball club ... the launch of a new campaign designed to ... infection MRSA and how regular hand-washing can help ...
... Seven years after becoming the Midwest,s first graduate school ... Chicago School of Professional Psychology is expanding its forensic ... to advance their career in the law and legal sectors. ... this fall at the school,s Chicago Campus at 325 N. ...
... had reduced risk of relapse or death, study finds ... non-Hodgkin lymphoma who drank wine before their diagnosis appeared ... according to a study that,s the first to identify ... 500 women with non-Hodgkin lymphoma and found that, overall, ...
Cached Medicine News:Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:NeoGenomics Schedules its Q1 2009 Earnings Release for April 23, 2009 2Health News:NeoGenomics Schedules its Q1 2009 Earnings Release for April 23, 2009 3Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2Health News:Pittsburgh Hospital Teams with Pirates Baseball Club in Unique Effort to Encourage Teen Handwashing, Prevent Spread of MRSA 2Health News:Pittsburgh Hospital Teams with Pirates Baseball Club in Unique Effort to Encourage Teen Handwashing, Prevent Spread of MRSA 3Health News:The Chicago School of Professional Psychology Announces Nation's First Psy.D. Program in Clinical Forensic Psychology 2Health News:The Chicago School of Professional Psychology Announces Nation's First Psy.D. Program in Clinical Forensic Psychology 3Health News:Wine May Guard Against Lymphoma Recurrence 2
Open 11 mm blades. Dull finish. Most popular size or model....
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Open 11 mm blades. Polished finish....
Open 10 mm blades. Dull finish....
Medicine Products: